Bayer’s compulsory licence appeal date set
India’s Intellectual Property Appellate Board will hear Bayer’s appeal of a controversial compulsory licence ruling on August 21 in Chennai, according to Pharmabiz.com
The Controller of Patents issued a compulsory licence in March to domestic generic drug maker Natco for the cancer treatment drug sorafenib.
The German pharmaceutical company filed its appeal with the country’s Intellectual Property...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.